Wintest
6721
D. Western Therapeutics Institute
4576
Ridge-i
5572
River Eletec
6666
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 0.00%97.92B | 9.70%420.4B | 4.53%127.49B | 12.18%102.18B | 16.42%92.81B | 8.23%97.92B | 16.30%383.24B | 14.18%121.96B | 12.32%91.09B | 14.66%79.72B |
Cost of revenue | 0.00%58.02B | 4.02%255.1B | 8.50%87.54B | 6.18%57.42B | 1.55%52.13B | -1.94%58.02B | 5.46%245.25B | -0.46%80.68B | 6.69%54.08B | 3.40%51.33B |
Gross profit | 0.00%39.9B | 19.79%165.3B | -3.23%39.95B | 20.96%44.76B | 43.30%40.69B | 27.45%39.9B | 42.31%137.99B | 60.25%41.28B | 21.72%37.01B | 42.80%28.39B |
Operating expense | 0.00%26.41B | 14.02%118.2B | 22.19%36.01B | 10.68%28.42B | 9.04%27.36B | 12.75%26.41B | 11.45%103.67B | 19.79%29.47B | 9.06%25.68B | 10.92%25.09B |
Operating profit | 0.00%13.49B | 37.21%47.1B | -66.68%3.94B | 44.25%16.34B | 303.76%13.33B | 71.12%13.49B | 770.06%34.32B | 919.07%11.81B | 65.19%11.33B | 220.56%3.3B |
Net non-operating interest income (expenses) | 0.00%-457M | -31.66%-2.09B | -39.31%-606M | -26.20%-525M | -31.25%-504M | -29.10%-457M | -11.98%-1.59B | -17.57%-435M | -18.86%-416M | -5.21%-384M |
Non-operating interest income | 0.00%25M | 9.38%105M | 8.33%26M | 8.00%27M | 12.50%27M | 8.70%25M | 0.00%96M | -7.69%24M | -16.67%25M | 20.00%24M |
Non-operating interest expense | 0.00%482M | 30.39%2.2B | 37.69%632M | 25.17%552M | 30.15%531M | 27.85%482M | 11.22%1.69B | 15.91%459M | 16.05%441M | 5.97%408M |
Net investment income | 2.38%819M | 370.78%5.83B | 9.49%669M | 1,562.32%4.72B | 7.99%-357M | 9.29%800M | 37.36%1.24B | 85.71%611M | -62.23%284M | -32.42%-388M |
Gain(Loss) on financial instruments designated as cash flow hedges | 0.00%-237M | -36.62%-526M | 0 | -661.11%-202M | -410.71%-87M | -4.41%-237M | -100.52%-385M | -222M | 36M | 28M |
Gain(Loss) on derecognition of available-for-sale financial assets | 0 | -3.00%2.17B | 149.52%930M | 168.89%605M | -92.64%254M | -13.47%379M | -12.90%2.24B | -315.12%-1.88B | -63.36%225M | 529.56%3.45B |
Income from associates and other participating interests | 546M | 0 | ||||||||
Special income (charges) | 0.00%8.44B | -209.76%-4.95B | -258.24%-7.28B | -652.49%-4.21B | -200.00%-1.89B | 3,800.44%8.44B | 273.01%4.51B | 381.01%4.6B | 3,413.04%762M | 37.00%-630M |
Less:Other special charges | 0.00%-8.44B | 110.30%806M | 153.54%4.24B | 680.45%4.42B | -8.41%577M | -3,800.44%-8.44B | -683.68%-7.83B | -583.19%-7.93B | -598.04%-762M | 884.38%630M |
Less:Write off | ---- | 24.65%4.14B | -8.46%3.04B | ---213M | ---- | ---- | -7.82%3.32B | 18.73%3.32B | --0 | ---- |
Other non-operating income (expenses) | 140.08%103M | 979.41%299M | -206.52%-1.36B | -1.33%222M | 1,532.69%1.7B | -413.41%-257M | -100.99%-34M | -194.68%-445M | 42.41%225M | -92.56%104M |
Income before tax | 0.00%22.15B | 20.05%48.38B | -122.57%-3.17B | 36.17%16.95B | 127.16%12.44B | 166.02%22.15B | 507.54%40.3B | 2,122.31%14.05B | 55.39%12.45B | 323.59%5.48B |
Income tax | 0.00%4.37B | 9.74%9.9B | -120.53%-906M | 43.58%4.2B | 488.39%2.23B | 235.87%4.37B | 244.28%9.02B | 234.22%4.41B | 191.41%2.93B | -31.46%379M |
Net income | 0.00%17.78B | 23.02%38.48B | -123.51%-2.26B | 33.90%12.75B | 100.27%10.21B | 153.10%17.78B | 142.71%31.28B | 145.75%9.63B | -15.12%9.52B | 269.77%5.1B |
Net income continuous operations | 0.00%17.78B | 23.02%38.48B | -123.50%-2.26B | 33.89%12.75B | 100.31%10.21B | 153.07%17.78B | 142.71%31.28B | 145.71%9.63B | -15.11%9.52B | 269.80%5.1B |
Noncontrolling interests | 0.00%-1M | -72.22%30M | 900.00%16M | 176.92%10M | -61.54%5M | -100.91%-1M | 129.67%108M | 98.29%-2M | 48.00%-13M | 124.53%13M |
Net income attributable to the company | 0.00%17.78B | 23.36%38.45B | -123.67%-2.28B | 33.63%12.74B | 100.65%10.21B | 157.15%17.78B | 135.22%31.17B | 138.68%9.63B | -15.20%9.53B | 272.32%5.09B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 0.00%17.78B | 23.36%38.45B | -123.67%-2.28B | 33.63%12.74B | 100.65%10.21B | 157.15%17.78B | 135.22%31.17B | 138.68%9.63B | -15.20%9.53B | 272.32%5.09B |
Gross dividend payment | ||||||||||
Basic earnings per share | 0.00%113.18 | 23.35%244.68 | -123.67%-14.51 | 33.61%81.05 | 100.62%64.96 | 157.17%113.18 | 135.19%198.36 | 138.65%61.31 | -15.21%60.66 | 272.33%32.38 |
Diluted earnings per share | 0.00%113.18 | 23.35%244.68 | -123.67%-14.5107 | 33.61%81.05 | 100.64%64.96 | 157.17%113.18 | 135.19%198.36 | 138.67%61.3098 | -15.20%60.66 | 272.31%32.377 |
Dividend per share | 0 | 0.00%93 | 0.00%93 | 0 | 0 | 0 | 0.00%93 | 0.00%93 | 0 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |